Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
thyroid cancer
Biotech
Eli Lilly axes next-generation, resistance-busting RET inhibitor
Lilly pushed the candidate, LOXO-260, into the clinic to overcome acquired resistance to existing drugs such as its own Retevmo.
Nick Paul Taylor
Feb 6, 2024 7:41am
FDA clears Koios Medical's breast, thyroid cancer-spotting AI
Dec 20, 2021 11:17am
Biopharma charts progress in translating CAR-T to solid cancers
Dec 15, 2021 3:00am
AffyImmune snags $30M for 'tune and track' platform for CAR-T
Oct 7, 2021 8:00am
Medtronic grows ENT business with 7th acquisition this year
Oct 30, 2020 12:13pm
Roche to pay Blueprint $775M for pralsetinib rights
Jul 14, 2020 6:55am
